ADMA ADMA Biologics Inc
Debt Financing ·
The agreement provides a $75 million term loan and a $225 million revolving credit facility, both maturing August 5, 2028. ADMA used the proceeds to pay off its earlier facility with Ares Capital Corporation.
ADMA Biologics said on March 3, 2025 that KPMG LLP has not finished its audit of 2024 and expects to file the annual report by March 18, 2025. The notice attaches unaudited 2024 net income of 197,673 thousand dollars, against a 2023 net loss of 28,239 thousand dollars.
ADMA Biologics is a U.S.-based commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-derived biologics for immunodeficient patients and others at risk for certain infectious diseases. It has three FDA-approved products, all marketed: ASCENIV and BIVIGAM, both intravenous immune globulin products for primary immunodeficiency, and Nabi-HB, a hepatitis B immune globulin for acute exposure to blood containing HBsAg. The company manufactures these products at its FDA-licensed plasma fractionation facility in Boca Raton, Florida. Its ADMA BioCenters subsidiary operates source plasma collection centers in the U.S., which supply plasma for manufacturing and sales to third parties. The pipeline includes SG-001, an S. pneumoniae hyperimmune globulin, for which a pilot-scale batch has been produced and animal studies are under way, with a pre-IND submission anticipated in fiscal year 2026. An FDA-approved yield enhancement process for ASCENIV and BIVIGAM is expected to increase production yields by 20% or more from the same starting source plasma volume. In December 2025 the company agreed to divest three plasma collection centers for $12.0 million.
| Product or program | What it is | Stage |
|---|---|---|
| ASCENIV | Intravenous immune globulin for primary humoral immunodeficiency in adults and adolescents | marketed |
| BIVIGAM | Intravenous immune globulin for primary immunodeficiency in adults and pediatric patients | marketed |
| Nabi-HB | Hepatitis B immune globulin for acute exposure to blood containing HBsAg | marketed |
| SG-001 | S. pneumoniae hyperimmune globulin | animal studies; pre-IND submission anticipated in fiscal year 2026 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $4.8 million | $1.8 million |
| Net income (loss) | $146.9 million | $197.7 million |
| Cash from operations | $50.4 million | $118.7 million |
| Cash and equivalents | $87.6 million | $103.1 million |
ADMA Biologics Inc trades under the ticker ADMA on NASDAQ.
ADMA Biologics Inc is listed on NASDAQ.
The SEC Central Index Key (CIK) for ADMA Biologics Inc is 1368514. Its filings are on SEC EDGAR.
223,984,680 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05.
Our directory records ADMA Biologics Inc under United States.
Our directory classifies ADMA Biologics Inc as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for ADMA Biologics Inc is US0008991046.
aibio.space lists ADMA Biologics Inc among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
ADMA Biologics is a U.S.-based commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-derived biologics for immunodeficient patients and others at risk for certain infectious diseases. It has three FDA-approved products, all marketed: ASCENIV and BIVIGAM, both intravenous immune globulin products for primary immunodeficiency, and Nabi-HB, a hepatitis B immune globulin for acute exposure to blood containing HBsAg.
ASCENIV: Intravenous immune globulin for primary humoral immunodeficiency in adults and adolescents Stage: marketed.
BIVIGAM: Intravenous immune globulin for primary immunodeficiency in adults and pediatric patients Stage: marketed.
ADMA Biologics Inc reported net income of $146.9 million for the fiscal year ended Dec 31, 2025, and generated $50.4 million of cash from operations, per its annual report to the SEC.
$4.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
$136.0 million in cash at Jun 30, 2026, per its 10-Q.
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,2.02,2.03,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio